120 related articles for article (PubMed ID: 14562338)
1. Improved chemical strategies for the targeted therapy of cancer.
Maison W; Frangioni JV
Angew Chem Int Ed Engl; 2003 Oct; 42(39):4726-8. PubMed ID: 14562338
[No Abstract] [Full Text] [Related]
2. Recent developments in taxane drug delivery.
Safavy A
Curr Drug Deliv; 2008 Jan; 5(1):42-54. PubMed ID: 18220550
[TBL] [Abstract][Full Text] [Related]
3. Targeted taxane therapy for cancer.
Whelan J
Drug Discov Today; 2002 Jan; 7(2):90-2. PubMed ID: 11790612
[No Abstract] [Full Text] [Related]
4. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
Gopin A; Pessah N; Shamis M; Rader C; Shabat D
Angew Chem Int Ed Engl; 2003 Jan; 42(3):327-32. PubMed ID: 12548691
[No Abstract] [Full Text] [Related]
5. Programmed co-delivery of paclitaxel and doxorubicin boosted by camouflaging with erythrocyte membrane.
Fu Q; Lv P; Chen Z; Ni D; Zhang L; Yue H; Yue Z; Wei W; Ma G
Nanoscale; 2015 Mar; 7(9):4020-30. PubMed ID: 25653083
[TBL] [Abstract][Full Text] [Related]
6. Nanocarriers in cancer clinical practice: a pharmacokinetic issue.
Giodini L; Re FL; Campagnol D; Marangon E; Posocco B; Dreussi E; Toffoli G
Nanomedicine; 2017 Feb; 13(2):583-599. PubMed ID: 27520727
[TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 1.
Walker K; Kibble A; Shumoogam J
IDrugs; 2007 Aug; 10(8):513-6. PubMed ID: 17665320
[No Abstract] [Full Text] [Related]
8. Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.
Miller ML; Roller EE; Zhao RY; Leece BA; Ab O; Baloglu E; Goldmacher VS; Chari RV
J Med Chem; 2004 Sep; 47(20):4802-5. PubMed ID: 15369381
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
10. Drug-targeting strategies in cancer therapy.
Huang PS; Oliff A
Curr Opin Genet Dev; 2001 Feb; 11(1):104-10. PubMed ID: 11163159
[TBL] [Abstract][Full Text] [Related]
11. 12,13-isotaxanes: synthesis of new potent analogs and X-ray crystallographic confirmation of structure.
Johnson RA; Dobrowolski PJ; Nidy EG; Gebhard I; Qualls SJ; Wicnienski NA; Kelly RC; Pitts TW; Lopes NM; DeKoning TF; Mattern SJ; Weed SD; McGovren JP; Chidester CG
J Med Chem; 1997 Aug; 40(18):2810-2. PubMed ID: 9288161
[No Abstract] [Full Text] [Related]
12. Paclitaxel prodrugs: toward smarter delivery of anticancer agents.
Skwarczynski M; Hayashi Y; Kiso Y
J Med Chem; 2006 Dec; 49(25):7253-69. PubMed ID: 17149855
[No Abstract] [Full Text] [Related]
13. [A case of irreversible cardiomyopathy induced by polychemotherapy].
Skopets IS; Vezikova NN; Ivanova EP; Sergeeva SS; Ignatenko OV
Ter Arkh; 2015; 87(12):73-76. PubMed ID: 26978422
[TBL] [Abstract][Full Text] [Related]
14. Arginine-rich CPPs for improved drug delivery to tumors.
Park K
J Control Release; 2012 Apr; 159(2):153. PubMed ID: 22578245
[No Abstract] [Full Text] [Related]
15. Macromolecules as taxane delivery systems.
Dosio F; Stella B; Arpicco S; Cattel L
Expert Opin Drug Deliv; 2011 Jan; 8(1):33-55. PubMed ID: 21142695
[TBL] [Abstract][Full Text] [Related]
16. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
Kouchakzadeh H; Safavi MS; Shojaosadati SA
Adv Protein Chem Struct Biol; 2015; 98():121-43. PubMed ID: 25819278
[TBL] [Abstract][Full Text] [Related]
17. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate.
Miller K; Erez R; Segal E; Shabat D; Satchi-Fainaro R
Angew Chem Int Ed Engl; 2009; 48(16):2949-54. PubMed ID: 19294707
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry and chemical biology of new generation taxane antitumor agents.
Ojima I; Geney R; Ungureanu IM; Li D
IUBMB Life; 2002; 53(4-5):269-74. PubMed ID: 12121008
[TBL] [Abstract][Full Text] [Related]
19. A novel targeting drug carrier to deliver chemical bonded and physical entrapped anti-tumor drugs.
Huang L; Song J; Chen B
Int J Pharm; 2014 May; 466(1-2):52-7. PubMed ID: 24607212
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.
Sawant RM; Cohen MB; Torchilin VP; Rokhlin OW
J Drug Target; 2008 Aug; 16(7):601-4. PubMed ID: 18686131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
